Becker's Healthcare April 1, 2025
Alexandra Murphy

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes.

The research, published April 1 in the Annals of Internal Medicine, showed the number of non-diabetic adults using these drugs — which are...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
CVS Caremark taps Omada on GLP-1 program
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps

Share This Article